Clinical trials
Idiopathic Pulmonary Fibrosis clinical trials
Below are recruiting idiopathic pulmonary fibrosis clinical trials, each written for real people, not researchers. We’re tracking 85 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05392881Recruiting
Lung disease biobank for adults followed at a university clinic
This study collects and stores samples and health information from adults being followed for interstitial lung disease or certain rare lung conditions. The goal is to help researchers study these diseases over time and improve future care.
Kansas City, KansasAges 18 years+ - NCT05571059RecruitingPhase 2
Ifetroban pills for idiopathic pulmonary fibrosis
This trial studies ifetroban, an oral medicine, in people with idiopathic pulmonary fibrosis (IPF) to see if it improves outcomes and is safe. It may be an option if your IPF is confirmed on lung scans and your lung function tests meet the trial thresholds.
La Mesa, CaliforniaAges 40 years+ - NCT05842681Recruiting
Azithromycin for early worsening of idiopathic pulmonary fibrosis
This trial studies whether adding azithromycin to standard care can help people whose idiopathic pulmonary fibrosis is starting to flare up (worsen) in the early stages. It’s mainly for adults who are not very sick and cannot require intensive breathing support.
AsyutAges 18–80 - NCT05975983RecruitingPhase 2
Oral treatment test for idiopathic pulmonary fibrosis
This Phase 2 study tests whether an oral medication (INS018_055) can help people with idiopathic pulmonary fibrosis (IPF). You may be a fit if your lung function is in a certain range and your condition is stable.
Birmingham, AlabamaAges 40 years+ - NCT05989698Recruiting
Validating a wearable cough monitor (C-mo)
This study tests a wearable device (C-mo) that monitors coughing. It is for people of all ages who are currently coughing and can cooperate with wearing a small sensor on their belly for a short time.
AlfenaAges 2 years+ - NCT06125327RecruitingPhase 2/Phase 3
SC1011 for idiopathic pulmonary fibrosis (IPF)
This trial tests a new medication called SC1011 taken twice a day, compared to a placebo, to see if it can help people with IPF. It is for patients who were diagnosed within the last 5 years and have moderate lung function.
Beijing, Beijing MunicipalityAges 40–80 - NCT06189820RecruitingPhase 2
FAP protein as a marker for fibrotic lung disease
This trial is looking at a protein called FAP in the blood of people with fibrotic lung diseases. It aims to understand how this protein might be used as a marker to help doctors better diagnose and track these conditions.
BrusselsAges 18 years+ - NCT06323876Recruiting
Using CT scans to personalize treatment for pulmonary fibrosis
This study uses detailed CT scans to find better ways to treat idiopathic pulmonary fibrosis (IPF). It may help doctors choose the right treatment for each person.
Charlottesville, VirginiaAges 40–101 - NCT07671911RecruitingPhase 3
Treating IPF-related chronic cough with extended-release nalbuphine
This study tests an extended-release tablet (nalbuphine) to reduce chronic coughing in people with IPF. It may help if your cough has lasted 8 weeks or more and is bothersome.
Loxahatchee Groves, FloridaAges 40 years+ - NCT06445686Recruiting
Monitoring Vital Signs in Idiopathic Pulmonary Fibrosis
This study monitors your vital signs before and after a sudden worsening (flare-up) of IPF. It uses a wearable device (Bora Band®) to track your health and help doctors better understand and manage these events.
RennesAges 18 years+ - NCT06238622RecruitingPhase 3
Long-term nerandomilast for pulmonary fibrosis follow-up
This trial offers long-term treatment with nerandomilast for people with pulmonary fibrosis who already completed an earlier nerandomilast study. It aims to see how safe and effective the drug is over a longer period.
Birmingham, AlabamaAges 18 years+ - NCT06567717RecruitingPhase 2
Zinc and vitamin B3 supplement for IPF
This trial tests whether adding zinc and nicotinamide riboside (a vitamin B3-like supplement) to standard IPF treatment can help improve lung function. It is for people with IPF who are already seeing a lung doctor and live in certain states.
Los Angeles, CaliforniaAges 50 years+ - NCT06644144Recruiting
P4O2: A study for people with lung scarring
This study is testing a new way to track lung scarring (fibrosis) over time in people with conditions like IPF, other fibrotic lung diseases, or early signs of scarring. It might help doctors understand how the disease changes.
Amsterdam, North HollandAges 18–80 - NCT06702228Recruiting
Precision care for pulmonary fibrosis in Ireland
This trial is for people with scarring lung disease (pulmonary fibrosis) in Ireland. It aims to better understand and care for the condition, especially in families. The study will look at medical data and may help improve diagnosis and treatment.
DublinAges 18–85 - NCT06714123RecruitingPhase 2
Senicapoc for worsening lung scarring
This trial tests if the drug senicapoc can help people whose lung scarring (pulmonary fibrosis) is getting worse despite standard care. It aims to slow down the decline in lung function.
Aarhus NAges 18 years+ - NCT06747923RecruitingPhase 2
SB17170 for Idiopathic Pulmonary Fibrosis (IPF)
This trial tests a new drug, SB17170, for people with IPF. It aims to see if the drug can help slow down lung damage. You may be eligible if you have a confirmed diagnosis of IPF and meet certain lung function criteria.
GoyangAges 40 years+ - NCT06756230Recruiting
Downhill walking exercise for IPF patients
This study tests whether downhill walking improves lung function and exercise ability in people with idiopathic pulmonary fibrosis (IPF). If you can walk on a treadmill and haven't been in a structured exercise program recently, you may qualify.
Istanbul, ÜsküdarAges 18–75 - NCT06853145RecruitingEarly Phase 1
Using a special MRI scan to study lung disease in IPF
This trial uses an advanced MRI technique with a special gas (hyperpolarized xenon-129) to look at lung function in people with idiopathic pulmonary fibrosis (IPF). It may help doctors better understand how the disease affects your lungs and could lead to improved care.
Charlottesville, VirginiaAges 18 years+ - NCT06909409Recruiting
Vitamin D and lung immune cells in lung fibrosis
This study looks at how vitamin D affects immune cells in the lungs of people with a lung scarring condition called idiopathic pulmonary fibrosis (IPF) or other similar lung diseases. It tests if vitamin D levels are linked to how these cells work.
Aarhus NAges 18 years+ - NCT07121413RecruitingPhase 2
Testing SV001 for Idiopathic Pulmonary Fibrosis
This trial tests a new drug called SV001 to see if it is safe and tolerable for people with idiopathic pulmonary fibrosis (IPF). If you have IPF and meet certain health criteria, this study may help find new treatment options.
ChengduAges 40 years+ - NCT07230288RecruitingPhase 2
Study of ABBV-142 for Idiopathic Pulmonary Fibrosis
This trial is testing a new antibody drug, ABBV-142, to see if it can reduce disease activity in adults with idiopathic pulmonary fibrosis (IPF). It may help if your IPF was diagnosed within the last 7 years and you meet certain health criteria.
Dothan, AlabamaAges 40 years+ - NCT07299695RecruitingPhase 3
IVIG for sudden worsening of IPF
This trial tests whether giving a medication called intravenous immunoglobulin (IVIG) can help people with IPF who are hospitalized for a sudden worsening of their lung condition. The treatment aims to reduce inflammation and improve recovery.
PátraiAges 18 years+ - NCT07312305Recruiting
Small airways test in idiopathic pulmonary fibrosis
This study measures how well the small airways in your lungs work if you have idiopathic pulmonary fibrosis (IPF). It aims to find better ways to assess the disease and could lead to improved care.
Milan, LombardyAges 18 years+ - NCT07332117Recruiting
Studying body changes in IPF and PPF patients starting anti-fibrotic drugs
This study uses safe, painless scans (like muscle ultrasound and a body composition test) to track changes in muscle and fat in patients with IPF or PPF who are starting anti-fibrotic medication. The goal is to better understand how these treatments affect your body.
LondonAges 18 years+
Hear when a new Idiopathic Pulmonary Fibrosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for idiopathic pulmonary fibrosis?
- Yes. Clin2 currently lists 85 recruiting idiopathic pulmonary fibrosis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a idiopathic pulmonary fibrosis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a idiopathic pulmonary fibrosis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.